MetaCap

Filana Therapeutics Inc. (FLNA)

NASDAQ: FLNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.6413+0.0813 (+14.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

FLNA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$32.26M
EPS (TTM)
-$0.87
Ex-dividend date
Dec 13, 2012
52-week range
0.39 – 3.45
Day range
0.5898 – 0.6528
Volume / Avg
1.32M / 2.09M
Beta
—

52-week range

$0.39$3.45

FLNA stock today

Shares of Filana Therapeutics (FLNA) finished higher on Nov 20 at $0.6413, a gain of 14.52% or $0.0813 per share, versus the S&P 500's 3.70% decline. Shares are 81.4% below their 52-week high of $3.45, set on Nov 26, 2025 and 64.4% above the 52-week low of $0.39, near the bottom of the past year's range. FLNA is down 67.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 77.7%.

Filana Therapeutics has posted a net loss over the last twelve months (EPS of -$0.87), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Filana Therapeutics

Company profile

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Richard Jon Barry
Headquarters
Austin, TX
Employees
17

Financial highlights

Full financials

Filana Therapeutics reported a net loss of $91.0 million, compared with a loss of $24.3 million a year earlier. Diluted earnings per share came in at -$1.88.

Filana Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-90.97M$-24.34M$-97.22M$-76.25M$-32.38M
EPS (diluted)$-1.88$-1.46$-2.32$-1.90$-0.82

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$6.50+913.57%

  • Strong buy 1
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.22 vs —

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$5.25
Ex-dividend date
Dec 13, 2012

FLNA news

All FLNA news

Filana Therapeutics peers

Health Care sector
FLNA peer companies
CompanyPrice% ChgMarket capCompare
GRDXGridAI Technologies Corp.3.16-8.41%$32.44Mvs FLNA
HYFTMindWalk Holdings Corp.0.6844-14.27%$32.56Mvs FLNA
ATNMActinium Pharmaceuticals Inc. (Delaware)1.05-1.87%$33.01Mvs FLNA
VERUVeru Inc.1.94-8.06%$33.08Mvs FLNA
CUECue Biopharma Inc.4.15-7.78%$34.69Mvs FLNA
SERSerina Therapeutics Inc.1.12-6.67%$29.76Mvs FLNA
NXTCNextCure Inc.6.45-4.87%$29.53Mvs FLNA
NNVCNanoViricides Inc.1.14-2.56%$29.13Mvs FLNA

Indexes, lists and sector

Filana Therapeutics stock FAQ

What is Filana Therapeutics's stock price today?

FLNA last traded at $0.6413 as of Nov 20, 4:00 PM EST, up 14.52% on the day. Prices are delayed at least 15 minutes.

Does Filana Therapeutics pay a dividend?

Yes. Filana Therapeutics pays $0.00 per share annually. The most recent dividend of $5.25 had an ex-dividend date of Dec 13, 2012.

Who is Filana Therapeutics's CEO?

Mr. Richard Jon Barry is the chief executive officer of Filana Therapeutics Inc., which has about 17 employees.

Has FLNA ever split its stock?

Yes. The most recent FLNA stock split was a 1-for-7 split on May 10, 2017.

What is the FLNA 52-week high?

The 52-week high for FLNA is $3.45 and the 52-week low is $0.39. The stock is currently 81.4% below its high.

Compare FLNA